How Dave Ricks keeps Lilly looking beyond its hit weight loss drugs [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
The popularity of the two GLP-1 treatments has made the Indianapolis-based drugmaker one of the world's most valuable companies. It has leapt ahead of Novo Nordisk, its closest rival in the weight loss drug market, and attained a market capitalization exceeding that of ExxonMobil or JPMorgan Chase. A 10-fold increase in Lilly's stock since 2018 has made millionaires of some of its employees — and several realtors and car dealers in the midsize Midwestern city it calls home. That has posed a leadership challenge for Ricks that other CEOs might love to have: How to keep people from basking in their success, and focus them instead on advancing Lilly's GLP-1 offerings and finding the next Mounjaro or Zepbound. Ricks, who has run the company since 2017, is setting a restless tone at the top: For all the success GLP-1s have had, they still only reach about one in 10 people in a country where 40% of all health spending goes to treating obesity-related complaints. “So we look at that as
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Lilly's obesity pill hits nearly 4000 prescriptions in second week after launch [Yahoo! Finance]Yahoo! Finance
- Eli Lilly slips as obesity scripts said to trail those for Novo's Wegovy [Seeking Alpha]Seeking Alpha
- Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026) [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk A/S (NVO) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d+)".MarketBeat
- Hims & Hers jumps 7% after expanding partnership with Eli Lilly [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/20/26 - Form 6-K
- 4/20/26 - Form 6-K
- 4/13/26 - Form 6-K
- NVO's page on the SEC website